Change in serum CXCL10 levels during anti-tuberculosis treatment depends on vitamin D status

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 4, 2014, Pages 466-469

  Hasan, Zahra ^a   Salahuddin, N ^b   Rao, N ^c   Aqeel, M ^b   Mahmood, F ^b   Ali, F ^b   Ashraf, M ^a   Rahman, F ^b   Mahmood, S ^a   Islam, M ^a   Dildar, B ^b   Anwer, T ^c   Oiighor, F ^b   Sharif, N ^b   Ullah, A R ^b  

^a AGA KHAN UNIVERSITY   (Pakistan)

^b AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^c DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

Author keywords

Biomarker; CXCL10; Tuberculosis; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; GAMMA INTERFERON INDUCIBLE PROTEIN 10; TUBERCULOSTATIC AGENT; 25-HYDROXYVITAMIN D; BIOLOGICAL MARKER; CXCL10 PROTEIN, HUMAN; VITAMIN D;

ADULT; ARTICLE; BLOOD ANALYSIS; CXCL10 GENE; DISEASE ASSOCIATION; DOWN REGULATION; DRUG TREATMENT FAILURE; FOLLOW UP; GENE EXPRESSION REGULATION; HUMAN; MAJOR CLINICAL STUDY; MONOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; TUBERCULOSIS; ANALOGS AND DERIVATIVES; BLOOD; CONTROLLED STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VITAMIN D DEFICIENCY;

ANTITUBERCULAR AGENTS; BIOLOGICAL MARKERS; CHEMOKINE CXCL10; HUMANS; TREATMENT OUTCOME; TUBERCULOSIS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84897131875     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0460     Document Type: Article

References (10)

1. Walzl G, Ronacher K, Hanekom W, Scriba T J, Zumla A. Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011; 11: 343-354.
2. Zhang R, Naughton D P. Vitamin D in health and disease: current perspectives. Nutr J 2010; 9: 65.
3. Coussens A K, Wilkinson R J, Hanifa Y, et al. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci USA 2012; 109: 15449-15454.
4. Martineau A R, Wilkinson K A, Newton S M, et al. IFN-gamma- and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J Immunol 2007; 178: 7190-7198. (Pubitemid 46847445)
5. Selvaraj P, Harishankar M, Singh B, Banurekha V V, Jawahar M S. Effect of vitamin D3 on chemokine expression in pulmonary tuberculosis. Cytokine 2012; 60: 212-219.
6. Salahuddin N, Ali F, Hasan Z, Rao N, Aqeel M, Mahmood F. Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [supplementary cholecalciferol in recovery from tuberculosis]: a randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis. BMC Infect Dis 2013; 13: 22.
7. Wesje C, Gustafson P, Nielsen J, et al. TBscore: signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course. Scan J Immunol 2008; 40: 111-120.
8. Brodie M J, Boobis A R, Hillyard C J, et al. Effect of rifampicin and isoniazid on vitamin D metabolism. Clin Pharmacol Ther 1982; 32: 525-530. (Pubitemid 13096730)
9. Rook G A, Steele J, Fraher L, et al. Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 1986; 57: 159-163. (Pubitemid 16232232)
10. Liu P T, Stenger S, Li H, Wenzel L, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311: 1770-1773.